AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15456674 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscular Relaxation (PMR)
Number of subjects: 44
Study 11519634 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 0 mg (placebo)
Number of subjects: 5
Study 11519634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 5
Study 11519634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 5
Study 11519634 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg
Number of subjects: 5
Study 9737832 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 75 microg
Number of subjects: 30
Study 9737832 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 150 microg
Number of subjects: 30
Study 9737832 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 300 microg
Number of subjects: 30
Study 9737832 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 600 microg
Number of subjects: 30
Study 9737832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7918915 — intervention group
Group type: EXPERIMENTAL
Intervention: Gore‐Tex membrane treatment
Number of subjects: 6
Study 7918915 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (no Gore‐Tex membrane)
Number of subjects: 6
Study 3339821 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients (predictions provided by computer)
Number of subjects: 112
Study 3339821 — intervention group
Group type: COMPARATOR
Intervention: Control patients (no predictions provided)
Number of subjects: 112
Study 31401340 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (5% PVP-I)
Number of subjects: 56
Study 31401340 — intervention group
Group type: COMPARATOR
Intervention: Preservative free artificial tears (AT)
Number of subjects: 56
Study 28716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar injection (1–2 mL; 15 orbits)
Number of subjects: 24
Study 28716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial canthal peribulbar injection (2–8 mL; PB-1; 16 orbits)
Number of subjects: 24
Study 28716684 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsomedial and ventrolateral peribulbar injections (each 1–4 mL; PB-2; 16 orbits)
Number of subjects: 24
Study 28716684 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 24
Study 26337247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration device (80 Hz, 5 minutes daily for 6 months)
Number of subjects: 109
Study 26337247 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 109
Study 26337247 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration device (80 Hz)
Number of subjects: 109
Study 26337247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vibration and Placebo)
Number of subjects: 109
Study 23222369 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC Chemotherapy + ATRA
Number of subjects: 285
Study 23222369 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline + ATRA
Number of subjects: 285
Study 23222369 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 285
Study 21682121 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol
Number of subjects: 90
Study 21682121 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol (2x 200 microg)
Number of subjects: 90
Study 21682121 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microg misoprostol (3x 200 microg)
Number of subjects: 90
Study 18647095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser application at 780 nm (35 J/cm², 70 mW, 20 sec per site) during subgingival scaling and root planing.
Number of subjects: 10
Study 18647095 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser application at 630 nm (8.8 J/cm², 35 mW, 10 sec) for healing after the procedure.
Number of subjects: 10
Study 18647095 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale for pain assessment during the procedure.
Number of subjects: 10
Study 17932854 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior chamber paracentesis (Group 1, 15 eyes)
Number of subjects: 30
Study 17932854 — intervention group
Group type: COMPARATOR
Intervention: No anterior chamber paracentesis (Group 2, 15 eyes)
Number of subjects: 30
Study 12859691 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10872566 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg losartan
Number of subjects: 273
Study 10872566 — intervention group
Group type: COMPARATOR
Intervention: 50 mg atenolol
Number of subjects: 273
Study 9171758 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent follow-up examinations (group 1)
Number of subjects: 597
Study 9171758 — intervention group
Group type: COMPARATOR
Intervention: Virtually no follow-up (group 2)
Number of subjects: 597
Study 8404183 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution computed tomography (HRCT)
Number of subjects: 134
Study 8404183 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 134
Study 3542850 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg b.i.d.
Number of subjects: 30
Study 3542850 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 500 mg b.i.d.
Number of subjects: 30
Study 30358711 — intervention group
Group type: EXPERIMENTAL
Intervention: CYC‐PERT (cyclic combination therapy adding progesterone to estrogen)
Number of subjects: 1532
Study 30358711 — intervention group
Group type: COMPARATOR
Intervention: CC‐PERT (continuous combined estrogen progestin therapy)
Number of subjects: 1532
Study 27732013 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic pride
Number of subjects: 0
Study 27732013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hubristic pride
Number of subjects: 0
Study 27732013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hubristic pride with self-transcendent value affirmation
Number of subjects: 0
Study 24375941 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 33
Study 24375941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21986390 — intervention group
Group type: EXPERIMENTAL
Intervention: Community outreach strategies including print materials and presentations at events
Number of subjects: 580
Study 19775763 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (loading dose 400 mg followed by 100 mg for 1 month)
Number of subjects: 40
Study 19775763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17914067 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 106
Study 17914067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 15662054 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy initial assessment and management
Number of subjects: 766
Study 15662054 — intervention group
Group type: COMPARATOR
Intervention: Routine practice
Number of subjects: 766
Study 12779015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant autologous tumour cell-lysate vaccine (6 applications at 4-week intervals after radical nephrectomy)
Number of subjects: 558
Study 12779015 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant treatment)
Number of subjects: 558
Study 12779015 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant autologous tumour cell-lysate vaccine
Number of subjects: 558
Study 10580024 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (75 mg/m2) given for 2.5 years, interrupted every 6 weeks for treatment with either high-dose methotrexate or teniposide plus cytarabine.
Number of subjects: 180
Study 10580024 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (75 mg/m2)
Number of subjects: 180
Study 8904679 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) administered as a loading dose at various points during surgery and followed by continuous infusion.
Number of subjects: 68
Study 1991426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd‐YAG laser phototherapy and CO2 laser treatment (Group A)
Number of subjects: 88
Study 1991426 — intervention group
Group type: COMPARATOR
Intervention: Closed Ferguson hemorrhoidectomy (Group B)
Number of subjects: 88
Study 1991426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 6371293 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) administered twice a day for 10 days
Number of subjects: 85
Study 6371293 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) administered three times a day for 10 days
Number of subjects: 85
Study 6371293 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Number of subjects: 85
Study 6371293 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) for bacterial pneumonia and lung abscess
Number of subjects: 85
Study 6371293 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) against chronic RTI
Number of subjects: 85
Study 6371293 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) against chronic RTI
Number of subjects: 85
Study 6371293 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg tobramycin (TOB) against chronic bronchitis
Number of subjects: 85
Study 6371293 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tobramycin (TOB) against chronic bronchitis
Number of subjects: 85
Study 31329470 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + on-road training
Number of subjects: 40
Study 31329470 — intervention group
Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 40
Study 31329470 — intervention group
Group type: EXPERIMENTAL
Intervention: Education + on-road + simulator training
Number of subjects: 40
Study 29347988 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (2 mg, Circadin®)
Number of subjects: 33
Study 29347988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29347988 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 33
Study 26305067 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 CG/GG SNP at rs738409
Number of subjects: 937
Study 26305067 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 937
Study 26305067 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 CG/GG genotype
Number of subjects: 937
Study 26305067 — intervention group
Group type: EXPERIMENTAL
Intervention: PNPLA3 genotype
Number of subjects: 937
Study 26305067 — intervention group
Group type: EXPERIMENTAL
Intervention: rs738409 SNP in PNPLA3
Number of subjects: 937
Study 25219475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided needling with subacromial corticosteroid injection
Number of subjects: 54
Study 25219475 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 54
Study 22933480 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administration of PHQ-9
Number of subjects: 51
Study 22933480 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil administration of PHQ-9
Number of subjects: 51
Study 21298836 — intervention group
Group type: EXPERIMENTAL
Intervention: 1550 nm Erbium fiber laser treatment, once a week for 8 successive treatments
Number of subjects: 20
Study 21298836 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated half of the forehead)
Number of subjects: 20
Study 17397112 — intervention group
Group type: EXPERIMENTAL
Intervention: quantile approximation method
Number of subjects: 0
Study 17397112 — intervention group
Group type: COMPARATOR
Intervention: random effects approach (DerSimonian and Laird)
Number of subjects: 0
Study 16244020 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic (20 mL of 2% lidocaine) administered through the epidural needle before catheter insertion
Number of subjects: 240
Study 16244020 — intervention group
Group type: COMPARATOR
Intervention: Control group (catheter group) with local anesthetic injected via the catheter after catheter insertion
Number of subjects: 240
Study 12438292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with high-normal arterial pressure (systolic pressure 133 mm Hg)
Number of subjects: 300
Study 12438292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with hypertensive arterial pressure (systolic pressure 163 mm Hg)
Number of subjects: 300
Study 12438292 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to standing in subjects with high-normal arterial pressure
Number of subjects: 300
Study 12438292 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis across all groups
Number of subjects: 300
Study 10806942 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Fuji Ortho glass ionomer cement (GC Industrial Co., Tokyo, Japan)
Number of subjects: 38
Study 10806942 — intervention group
Group type: COMPARATOR
Intervention: System 1+ composite resin (Ormco Corp., Glendora, CA)
Number of subjects: 38
Study 7491367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkobene (3 x 40 mg daily for 57 days)
Number of subjects: 48
Study 7491367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2255512 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 271
Study 2255512 — intervention group
Group type: COMPARATOR
Intervention: Timolol maleate 0.5%
Number of subjects: 271
Study 461778 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 12765
Study 30102438 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature based on sagittal T1 CE and T2 MRI sequences
Number of subjects: 143
Study 28380053 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 2434
Study 28380053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2434
Study 25742529 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace fitness and education program (4 months of exercise training in 15-minute sessions)
Number of subjects: 60
Study 23707312 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of M1 (2 mA, 15 min)
Number of subjects: 0
Study 23707312 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS of PPC (2 mA, 15 min)
Number of subjects: 0
Study 23707312 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 0
Study 21802939 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250mg/d
Number of subjects: 173
Study 21802939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 19457670 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading of an outstretched arm (weight dropped into a receptacle)
Number of subjects: 19
Study 16923090 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (50% dextrose in 500 ml of water; regular insulin, 125 IU; potassium, 80 mmol) at 0.75 ml/kg/h
Number of subjects: 82
Study 16923090 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose in water
Number of subjects: 82
Study 15295413 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubidium 82 PET quantification of perfusion reserve
Number of subjects: 23
Study 11806646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% strontium chloride
Number of subjects: 10
Study 11806646 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% sodium fluoride
Number of subjects: 10
Study 11806646 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% formalin
Number of subjects: 10
Study 11806646 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate
Number of subjects: 10
Study 11806646 — intervention group
Group type: COMPARATOR
Intervention: Control (triple distilled water)
Number of subjects: 10
Study 9801529 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy enhancing interventions (role modeling, verbal persuasion, physiological feedback)
Number of subjects: 77
Study 9801529 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 77
Study 7712668 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (regimen A): 60 mg/kg intravenous foscarnet and 3.75 mg/kg ganciclovir
Number of subjects: 13
Study 7712668 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alternating therapy (regimen B): 120 mg/kg foscarnet and 6 mg/kg ganciclovir
Number of subjects: 13
Study 2664883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranylcypromine
Number of subjects: 45
Study 2664883 — intervention group
Group type: COMPARATOR
Intervention: L‐5‐hydroxytryptophan (L‐5HTP)
Number of subjects: 45
Study 2664883 — intervention group
Group type: COMPARATOR
Intervention: Nomifensine
Number of subjects: 45
Study 705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training with maximum intensity (interval training 2 X 60 min a week for 12 months)
Number of subjects: 15
Study 705283 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained)
Number of subjects: 15
Study 705283 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training with maximum intensity
Number of subjects: 15
Study 31991513 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose nitroglycerin (5 µg·kg‐1 ·min‐1)
Number of subjects: 42
Study 31991513 — intervention group
Group type: COMPARATOR
Intervention: Low-dose nitroglycerin (1 µg·kg‐1 ·min‐1)
Number of subjects: 42
Study 31093677 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 (80 mg, day -1 to day 2)
Number of subjects: 206
Study 31093677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 28355756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg/kg intravenously before induction and followed by 2.0 mg·kg(‐1)·h(‐1) to the end of surgery
Number of subjects: 60
Study 28355756 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine group
Number of subjects: 60
Study 28355756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 25474182 — intervention group
Group type: EXPERIMENTAL
Intervention: Brody CT scores
Number of subjects: 60
Study 23529800 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate 1 mg once a day for 24 months
Number of subjects: 704
Study 23529800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 704
Study 21253777 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet treatment for 12 months
Number of subjects: 320
Study 19938933 — intervention group
Group type: EXPERIMENTAL
Intervention: Bartenders trained in responsible beverage service programs
Number of subjects: 596
Study 19938933 — intervention group
Group type: COMPARATOR
Intervention: Control bartenders (not trained)
Number of subjects: 596
Study 16165158 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75-225mg/day)
Number of subjects: 308
Study 16165158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60mg/day)
Number of subjects: 308
Study 16165158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 15529377 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-3 mg/kg infliximab
Number of subjects: 1049
Study 15529377 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-6 mg/kg infliximab
Number of subjects: 1049
Study 15529377 — intervention group
Group type: COMPARATOR
Intervention: MTX-placebo
Number of subjects: 1049
Study 11527433 — intervention group
Group type: EXPERIMENTAL
Intervention: Verification of properties using local representation (e.g., verifying 'mane' for PONY after verifying 'mane' for HORSE)
Number of subjects: 0
Study 11527433 — intervention group
Group type: COMPARATOR
Intervention: Verification of properties using global representation (e.g., verifying 'mane' for PONY after verifying 'mane' for LION)
Number of subjects: 0
Study 9692703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg b.d. (Group A)
Number of subjects: 273
Study 9692703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) 400 mg b.d. for 4 weeks + clarithromycin 500 mg t.d.s. (Group B)
Number of subjects: 273
Study 30105991 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.3% gel
Number of subjects: 0
Study 30105991 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.05% cream
Number of subjects: 0
Study 29096681 — intervention group
Group type: EXPERIMENTAL
Intervention: SlowMo intervention added to treatment as usual (TAU)
Number of subjects: 360
Study 29096681 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 360
Study 26237622 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) therapy, 50 mg/kg bolus immediately after induction of anesthesia followed by another 50 mg/kg infusion over 3 hours (total dose, 100 mg/kg)
Number of subjects: 363
Study 26237622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 26237622 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (Mg) therapy
Number of subjects: 363
Study 23759000 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation (RSD)
Number of subjects: 200
Study 23759000 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 200
Study 19067437 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple suicide attempts
Number of subjects: 121
Study 19067437 — intervention group
Group type: COMPARATOR
Intervention: One or no suicide attempts
Number of subjects: 121
Study 17604955 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Blalock-Taussig (BT) shunt
Number of subjects: 17
Study 17604955 — intervention group
Group type: COMPARATOR
Intervention: Right ventricle to pulmonary artery (RV-PA) conduit
Number of subjects: 17
Study 15453909 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the morning
Number of subjects: 63
Study 15453909 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (12.7 g daily) taken in the evening
Number of subjects: 63
Study 15453909 — intervention group
Group type: COMPARATOR
Intervention: Control (no psyllium administration)
Number of subjects: 63
Study 11268113 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% peppermint oil
Number of subjects: 41